290 related articles for article (PubMed ID: 26515728)
1. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
[TBL] [Abstract][Full Text] [Related]
2. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
3. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
[TBL] [Abstract][Full Text] [Related]
6. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
[TBL] [Abstract][Full Text] [Related]
7. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
8. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
Saung MT; Zheng L
Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
Lutz ER; Wu AA; Bigelow E; Sharma R; Mo G; Soares K; Solt S; Dorman A; Wamwea A; Yager A; Laheru D; Wolfgang CL; Wang J; Hruban RH; Anders RA; Jaffee EM; Zheng L
Cancer Immunol Res; 2014 Jul; 2(7):616-31. PubMed ID: 24942756
[TBL] [Abstract][Full Text] [Related]
10. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
Blair AB; Kleponis J; Thomas DL; Muth ST; Murphy AG; Kim V; Zheng L
J Clin Invest; 2019 Apr; 129(4):1742-1755. PubMed ID: 30747725
[TBL] [Abstract][Full Text] [Related]
11. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
Le DT; Lutz E; Uram JN; Sugar EA; Onners B; Solt S; Zheng L; Diaz LA; Donehower RC; Jaffee EM; Laheru DA
J Immunother; 2013 Sep; 36(7):382-9. PubMed ID: 23924790
[TBL] [Abstract][Full Text] [Related]
13. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
Wu AA; Bever KM; Ho WJ; Fertig EJ; Niu N; Zheng L; Parkinson RM; Durham JN; Onners B; Ferguson AK; Wilt C; Ko AH; Wang-Gillam A; Laheru DA; Anders RA; Thompson ED; Sugar EA; Jaffee EM; Le DT
Clin Cancer Res; 2020 Oct; 26(19):5129-5139. PubMed ID: 32591464
[TBL] [Abstract][Full Text] [Related]
15. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
16. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
Tang Y; Xu X; Guo S; Zhang C; Tang Y; Tian Y; Ni B; Lu B; Wang H
PLoS One; 2014; 9(3):e91551. PubMed ID: 24637664
[TBL] [Abstract][Full Text] [Related]
17. Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy.
Liang SC; Moskalenko M; Van Roey M; Jooss K
Clin Immunol; 2013 Aug; 148(2):287-98. PubMed ID: 23811319
[TBL] [Abstract][Full Text] [Related]
18. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
[TBL] [Abstract][Full Text] [Related]
19. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
20. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.
Takaku S; Terabe M; Ambrosino E; Peng J; Lonning S; McPherson JM; Berzofsky JA
Int J Cancer; 2010 Apr; 126(7):1666-74. PubMed ID: 19830696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
